Ors had a larger percentage of DDR mutations than kind I tumors (70.59 vs. 28.85 , p 0.001, chi-squared test). The advancedBiomedicines 2021, 9,9 ofstage individuals had higher percentage of DDR mutations than the early-stage individuals (57.28 vs. 27.54 , p 0.001, chi-squared test). Recurring sufferers had a larger percentage of DDR mutations than those devoid of recurrence (53.92 vs. 32.86 , p = 0.006, chi-squared test). Patients who died of EOC had a larger percentage of DDR mutations than living patients (59.21 vs. 34.38 , p = 0.001, chi-squared test). EOC patients without DDR gene mutation had longer progression-free survival (PFS) (p = 0.0072, log-rank test, Figure 2A) and overall survival (OS) (p = 0.022, log-rank test, Figure 2B) than these with 1 DDR or two DDR mutations. In serous carcinoma, patients with or without DDR mutations had comparable PFS (p = 0.56, log-rank test, Figure 2C). Sufferers with two DDR mutations had a trend of much better OS than those with 1 mutation or none, nevertheless it was not statistically important (p = 0.47, log-rank test, Figure 2D). In endometrioid carcinoma, individuals with two DDR gene mutations had shorter PFS (p = 0.0035, log-rank test, Figure 2E) and OS (p = 0.015, log-rank test, Figure 2F) than those with 1 mutation or none. In clear cell carcinoma, sufferers with two DDR gene mutations had drastically shorter PFS (p = 0.0056, log-rank test, Figure 2G) and OS (p = 0.0046, log-rank test, Figure 2H) than these with 1 DDR mutation or none. Tumor recurrence with CCR gene mutation (HR: 1.68 (1.12.50), p = 0.011), 1 DDR gene mutation (HR: 1.71 (1.12.60), p = 0.013), endometrioid Flusilazole manufacturer carcinoma (HR: 0.17 (0.08.37), p 0.001), form II tumor (HR: two.69 (1.81.00), p 0.001), advanced-stage carcinoma (HR: five.29 (three.16.85), p 0.001), high-grade tumor (HR: 5.57 (two.263.70), p 0.001) and optimal debulking surgery (HR: 0.28 (0.18.41), p 0.001) have been significant inside the univariate Cox regression model (Table five). Advanced-stage carcinoma (HR: three.08 (1.63.80), p = 0.001) and optimal debulking surgery (HR: 0.51 (0.32.80), p = 0.004) were significant prognostic aspects in the multivariate evaluation. Cancer-related death with TLS gene mutation (HR: 33.76 (three.9589.00), p = 0.001), 1 DDR gene mutation (HR: 1.96 (1.20.20), p = 0.007), endometrioid carcinoma (HR: 0.12 (0.04.38), p 0.001), type II tumor (HR: 1.88 (1.19.96), p = 0.007), advanced-stage carcinoma (HR: six.84 (three.284.25), p 0.001), high-grade tumor (HR: 17.97 (2.5029.29), p = 0.004) and optimal debulking surgery (HR: 0.26 (0.16.41), p 0.001) were important inside the univariate Cox regression model. Variety II tumor (HR: 0.35 (0.20.60), p 0.001), TLS gene mutation (HR: 9.57 (1.084.83), p = 0.042), advanced-stage carcinoma (HR: four.82 (2.091.09), p 0.001) and optimal debulking surgery (HR: 0.38 (0.22.64), p 0.001) had been critical prognostic factors within the multivariate analysis.Biomedicines 2021, 9,ten ofTable four. The correlation of DDR gene mutations with clinical parameters in the Hexythiazox Description epithelial ovarian cancer sufferers. Genes OSA Total HR Wild form Mutation p worth NHEJ Wild type Mutation p value MMR Wild sort Mutation p value BER Wild kind Mutation p value 160 93.02 12 6.98 65 94.20 four five.80 37 94.87 two 5.13 58 90.63 6 9.38 0.631 96 92.31 eight 7.69 64 94.12 4 five.88 0.649 65 94.20 4 five.80 95 92.23 8 7.77 0.619 27 93.10 two six.90 133 93.01 ten 6.99 0.985 66 94.29 4 5.71 94 92.16 8 7.84 0.59 91 94.79 5 five.21 69 90.79 7 9.21 0.306 161 93.60 11 six.40 67 97.ten two 2.90 33 84.62 six 15.38 61.